Transgene Sa Stock Price To Earning
| TRGNF Stock | USD 1.59 0.00 0.00% |
Transgene SA fundamentals help investors to digest information that contributes to Transgene's financial success or failures. It also enables traders to predict the movement of Transgene Pink Sheet. The fundamental analysis module provides a way to measure Transgene's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Transgene pink sheet.
Transgene |
Transgene SA Company Price To Earning Analysis
Transgene's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current Transgene Price To Earning | (7.42) X |
Most of Transgene's fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Transgene SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
| Competition |
Based on the latest financial disclosure, Transgene SA has a Price To Earning of -7.42 times. This is 128.72% lower than that of the Healthcare sector and 250.51% lower than that of the Biotechnology industry. The price to earning for all United States stocks is 125.84% higher than that of the company.
Transgene Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Transgene's direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Transgene could also be used in its relative valuation, which is a method of valuing Transgene by comparing valuation metrics of similar companies.Transgene is currently under evaluation in price to earning category among its peers.
Transgene Fundamentals
| Return On Equity | -0.36 | |||
| Return On Asset | -0.16 | |||
| Profit Margin | (1.27) % | |||
| Operating Margin | (1.39) % | |||
| Current Valuation | 152.15 M | |||
| Shares Outstanding | 100.2 M | |||
| Shares Owned By Institutions | 1.70 % | |||
| Price To Earning | (7.42) X | |||
| Price To Book | 0.02 X | |||
| Price To Sales | 10.71 X | |||
| Revenue | 9.99 M | |||
| Gross Profit | (15.87 M) | |||
| EBITDA | (16.55 M) | |||
| Net Income | (19.54 M) | |||
| Cash And Equivalents | 49.57 M | |||
| Cash Per Share | 0.50 X | |||
| Debt To Equity | 0.25 % | |||
| Current Ratio | 4.27 X | |||
| Book Value Per Share | 0.55 X | |||
| Cash Flow From Operations | (31.94 M) | |||
| Earnings Per Share | (0.23) X | |||
| Number Of Employees | 143 | |||
| Beta | 0.79 | |||
| Market Capitalization | 212.74 M | |||
| Total Asset | 101.84 M | |||
| Retained Earnings | (500 M) | |||
| Working Capital | 27 M | |||
| Current Asset | 51 M | |||
| Current Liabilities | 24 M | |||
| Z Score | -5.6 | |||
| Net Asset | 101.84 M |
About Transgene Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Transgene SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Transgene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Transgene SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Transgene Pink Sheet
Transgene financial ratios help investors to determine whether Transgene Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Transgene with respect to the benefits of owning Transgene security.